Drug class | Drug | Mechanism of action | Clinical trials (phase) | Study design | Disease |
---|---|---|---|---|---|
Tumor epigenetics | Entinostat | Histone deacetylase (HDAC) inhibitor | NCT02437136 (1/2) | Combination | NSCLC |
HBI-8000 | NCT02718066 (1/2) | Combination | NSCLC | ||
ACY 241 | NCT02635061 (1) | Combination | NSCLC | ||
Epacadostat | NCT02298153 (1) | Combination | NSCLC | ||
Mocentinostat | NCT02805660 (1/2) | Combination | NSCLC | ||
CC-486 | DNA hypomethylation | NCT02250326 (2) | Combination | NSCLC | |
Azacitidine | NCT02009436 (1) | Monotherapy | NSCLC | ||
RRX-001 | DNA methylation, histone deacetylation, and lysine demethylation | NCT02489903 (2) | Monotherapy | NSCLC | |
Tumor metabolism | Ethaselen | Thioredoxin reductase | NCT02166242 (1) | Monotherapy | NSCLC |
TAS-114 | dUTPase | NCT02855125 (2) | Combination | NSCLC | |
ADI-PEG 20 | Pegylated arginine deiminase | NCT02029690 (1) | Combination | NSCLC | |
CCT245737 | Checkpoint kinase 1 | NCT02797977 (1) | Combination | NSCLC/SCLC | |
LY2606368 | NCT02860780 (1) | Combination | NSCLC/SCLC | ||
CB-839 | Glutaminase | NCT02771626 (1/2) | Combination | NSCLC | |
Immunotherapy | Cancer vaccines | ||||
CV301 | Tumor peptide vaccine | NCT02840994 (1/2) | Combination | NSCLC | |
TG4010 | NCT02823990 (2) | Combination | NSCLC | ||
Gemogenovatucel-T | NCT02639234 (2) | Combination | NSCLC | ||
CMB305 | NCT02387125 (1) | Monotherapy | NSCLC | ||
DC-CIK | Dendritic cell vaccine | NCT02688686 (1/2) | Monotherapy | NSCLC | |
DCVAC/LUCA | NCT02470468 (1/2) | Monotherapy | NSCLC | ||
AGS-003-LNG | NCT02662634 (2) | Monotherapy | NSCLC | ||
JNJ-64041757 | Listeria vaccine | NCT02592967 (1) | Monotherapy | NSCLC | |
ADXS11-001 | NCT02531854 (2) | Combination | NSCLC | ||
DSP-7888 | WT1 vaccine | NCT02498665 (1) | Monotherapy | NSCLC | |
S-588410 | (HLA)-a*2402-restricted epitope peptides | NCT02410369 (2) | Monotherapy | NSCLC | |
AD-MAGEA3 and MG1-MAGEA3 | MAGE-A3-expressing maraba virus | NCT02879760 (1/2) | Monotherapy | NSCLC | |
L-DOS47 | Immunoconjugate | NCT02340208 (1/2) | Monotherapy | NSCLC | |
NCT02309892 (1) | Monotherapy | NSCLC | |||
DRibbles | NCT01909752 (2) | Monotherapy | NSCLC | ||
Checkpoint inhibitors | |||||
Enoblituzumab (MGA271) | B7-H3 antibody | NCT02475213 (1) | Combination | NSCLC | |
NCT01391143 (1) | Monotherapy | NSCLC | |||
MGD009 | NCT02628535 (1) | Monotherapy | NSCLC | ||
CM-24 | CEACAM1 antibody | NCT02346955 (1) | Combination | NSCLC | |
Indoximod | Indoleamine 2,3-dioxygenase (IDO) inhibitor | NCT02460367 (1/2) | Combination | NSCLC | |
AMG 820 | Colony-stimulating factor 1 receptor (CSF1R) | NCT02713529 (1/2) | Combination | NSCLC | |
PF-05082566 | 4-1BB agonist | NCT02315066 (1) | Combination | NSCLC/SCLC | |
PBF-509 | Adenosine A2a | NCT02403193 (1/2) | Combination | NSCLC | |
CPI-444 | NCT02655822 (1) | Combination | NSCLC | ||
PF-04518600 | Anti-OX40 mAb | NCT02315066 (1) | Combination | NSCLC/SCLC | |
JNJ-61610588 | Anti-VISTA | NCT02671955 (1) | Monotherapy | NSCLC/SCLC | |
PDR001 | Anti-PD1 | NCT02460224 (1/2) | Combination | NSCLC/SCLC | |
CA-170 | Oral PDL1/PDL2/VISTA inhibitor | NCT02812875 (1) | Monotherapy | NSCLC/SCLC | |
Avelumab | PD- L1 inhibitor | NCT02584634 (2) | Combination | NSCLC | |
Varlilumab | Anti-CR27 mAb | NCT02335918 (1) | Combination | NSCLC | |
JNJ-64457107 | Anti- CD40 | NCT02829099 (1) | Monotherapy | NSCLC/SCLC | |
Modified T cell therapy | |||||
TIL | Tumor infiltrating lymphocytes | NCT02133196 (2) | Monotherapy | NSCLC | |
DC-CTL | Combined dendritic cells- cytotoxic t lymphocyte | NCT02766348 (2) | Monotherapy | NSCLC | |
NCT02886897 (1/2) | Combination | NSCLC | |||
IMMUNICELL® | Autologous γδ- T lymphocytes | NCT02459067 (2/3) | Monotherapy | NSCLC | |
MAGE A10c796T | Chimeric antigen receptor T lymphocytes | NCT02592577 (1/2) | Monotherapy | NSCLC | |
NY-ESO-1c259T | NCT02588612 (1/2) | Monotherapy | NSCLC | ||
ANTI-MUC1 CAR T | NCT02587689 (1/2) | Monotherapy | NSCLC | ||
PD1 knockout cells | Modified T cell therapy | NCT02793856 (1) | Monotherapy | NSCLC | |
Targeted NK cells | Modified NK cell therapy | NCT02118415 (2) | Monotherapy | NSCLC | |
NCT02845856 (1/2) | Combination | NSCLC | |||
WT1-TCRC4-T cells | WT1 targeted t cells | NCT02408016 (1/2) | Monotherapy | NSCLC | |
Cytokines | |||||
rSIFN-co | Recombinant interferon | NCT02387307 (1) | Monotherapy | NSCLC | |
ALT-803 | IL- 15 agonist | NCT02523469 (1/2) | Combination | NSCLC | |
AM0010 | Pegylated IL-10 | NCT02009449 (1) | Monotherapy | NSCLC | |
AAT-007 | Prostaglandin E receptor subtype 4 | NCT02538432 (2) | Monotherapy | NSCLC | |
Poly-ICL | Toll-like receptor agonist | NCT02661100 (1/2) | Combination | NSCLC/SCLC | |
VTX-2337 | NCT02650635 (1) | Monotherapy | NSCLC | ||
L19-IL2 | Antibody cytokine fusion protein | NCT02735850 (2) | Combination | NSCLC | |
CDX-1401 | DEC-205/NY-eso-1 fusion protein | NCT02661100 (1/2) | Combination | NSCLC/SCLC | |
Targeted therapy | EGFR inhibitors | ||||
ABBV-221 | EGFR | NCT02365662 (1) | Monotherapy | NSCLC | |
AC0010MA | EGFR T790M | NCT02448251 (1/2) | Monotherapy | NSCLC | |
Tesevatinib | EGFR (CNS penetrant) | NCT02616393 (2) | Monotherapy | NSCLC | |
JNJ-61186372 | EGFR/MET bispecific mAb | NCT02609776 (1) | Monotherapy | NSCLC | |
AP32788 | EGFR exon 20 | NCT02716116 (1/2) | Monotherapy | NSCLC | |
MM-151 and MM-121 | EGFR mAb | NCT02538627 (1) | Monotherapy | NSCLC | |
TargomiRs | EGFR ab bound mir-16 | NCT02369198 (1) | Monotherapy | NSCLC | |
Multi-kinase inhibitors | |||||
Navitoclax | Bcl-2, Bcl-x, Bcl-w | NCT02520778 (1) | Combination | NSCLC | |
CT-707 | ALK, FAK, Pyk2 | NCT02695550 (1) | Monotherapy | NSCLC | |
Famitinib | c-Kit, VEGFR2, PDGFR, VEGFR3, FLT1, FLT3 | NCT02356991 (2) | Monotherapy | NSCLC | |
NCT02364362 (1) | Combination | NSCLC | |||
MGCD516 | VEGFR, PDGFR, DDR2, TRK and Eph families | NCT02219711 (1) | Monotherapy | NSCLC/SCLC | |
Pexidartinib | Kit, FLT3, CAF1r | NCT02452424 (1/2) | Combination | NSCLC | |
Anlotinib | VEGF1/2/3, FGFR2 | NCT02388919 (2/3) | Monotherapy | NSCLC | |
Entrectinib | NTRK1/2/3, ROS1, ALK | NCT02568267 (2) | Monotherapy | NSCLC | |
ASP2215 | Axl, FLT3 | NCT02495233 (1/2) | Combination | NSCLC/SCLC | |
PI3K/mTOR pathway inhibitors | |||||
MLN1117 | PI3K | NCT02393209 (1/2) | Combination | NSCLC | |
AZD8186 | NCT01884285 (1) | Monotherapy | NSCLC | ||
LY3023414 | PI3K, mTOR | NCT02443337 (2) | Combination | NSCLC | |
Other miscellaneous target inhibitors | |||||
LEE011 | CDK 4/6 | NCT02292550 (1/2) | Combination | NSCLC | |
Abemaciclib | NCT02308020 (2) | Monotherapy | NSCLC | ||
NCT02779751 (2) | Monotherapy | NSCLC | |||
NCT02079636 (1) | Combination | NSCLC | |||
INK128 | TORC1/2 | NCT02503722 (1) | Combination | NSCLC | |
Alisertib | Aurora kinase inhibitor | NCT01471964 (1/2) | Combination | NSCLC | |
Ibrutinib | BTK | NCT02321540 (1/2) | Monotherapy | NSCLC | |
TAK-659 | Syk | NCT02834247 (1) | Combination | NSCLC | |
Pyrotinib | HER2 | NCT02535507 (2) | Monotherapy | NSCLC | |
EphB4-HSA | sEphB4 | NCT02495896 (1) | Combination | NSCLC | |
Ficlatuzumab | Hepatocyte growth factor (HGF) | NCT02318368 (2) | Combination | NSCLC | |
AMG 479 | IGFR-1 | NCT01061788 (1) | Combination | NSCLC/SCLC | |
MM-121 | HER3 | NCT02387216 (2) | Combination | NSCLC | |
Defactinib | Focal adhesion kinase (FAK) | NCT02758587 (1/2) | Combination | NSCLC | |
JNJ-42756493 | FGFR | NCT02699606 (2) | Monotherapy | NSCLC | |
INCB054828 | NCT02393248 (1/2) | Monotherapy | NSCLC/SCLC | ||
LOXO-101 | NTRK1/2/3 | NCT02576431 (2) | Monotherapy | NSCLC/SCLC | |
RXDX-101 | NCT02097810 (1) | Monotherapy | NSCLC/SCLC | ||
Rh-endostatin | NCT02375022 (2) | Combination | NSCLC | ||
Cediranib | NCT02498613 (2) | Combination | NSCLC/SCLC | ||
GSK3052230 | FGF ligand trap | NCT01868022 (1) | Combination | NSCLC/SCLC | |
TRC105 | Endoglin (CD105) | NCT02429843 (1) | Combination | NSCLC | |
MEK162 | MEK | NCT01859026 (1) | Combination | NSCLC | |
PD-0325901 | NCT02022982 (1/2) | Combination | NSCLC | ||
Selumetinib | RAS/RAF/MEK/ERK | NCT01586624 (1) | Combination | NSCLC | |
Pacritnib | JAK2 | NCT02342353 (1/2) | Monotherapy | NSCLC | |
AT13387 | Heat shock protein 90 | NCT02535338 (1/2) | Combination | NSCLC | |
AUY922 | NCT01922583 (2) | Monotherapy | NSCLC | ||
NCT01854034 (2) | Monotherapy | NSCLC | |||
Galunisertib | TGFβ signaling | NCT02423343 (1/2) | Combination | NSCLC/SCLC | |
MSC2156119J | MET | NCT01982955 (1/2) | Combination | NSCLC | |
Ralimetinib | MAPK | NCT02860780 (1) | Combination | NSCLC/SCLC | |
LTT462 | NCT02711345 (1) | Monotherapy | NSCLC | ||
PF-06671008 | P-cadherin | NCT02659631 (1) | Monotherapy | NSCLC/SCLC | |
BGB324 | Axl | NCT02424617 (1/2) | Combination | NSCLC | |
DNA repair | VX790 | ATR | NCT02487095 (1/2) | Combination | SCLC |
Veliparib | PARP | NCT01386385 (1/2) | Combination | NSCLC | |
Olaparib | NCT02498613 (2) | Combination | NSCLC/SCLC | ||
Chemotherapy | Plinabulin | Tubulin-depolymerization | NCT02846792 (1/2) | Combination | NSCLC |
NCT02812667 (1) | Combination | NSCLC | |||
PT-112 | Platinum based | NCT02884479 (1/2) | Combination | NSCLC/SCLC | |
NC-6004 | Micellar nanoparticle-encapsulated cisplatin | NCT02240238 (1/2) | Combination | NSCLC | |
EC1456 | Folic acid-tubulysin conjugate | NCT01999738 (1) | Monotherapy | NSCLC/SCLC | |
Oncolytic virus | CVA21 | Coxsackievirus A21 | NCT02043665 (1) | Monotherapy | NSCLC |
NCT02824965 (1) | Combination | NSCLC |